BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17646421)

  • 1. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
    Rodríguez-Tudela JL; Almirante B; Rodríguez-Pardo D; Laguna F; Donnelly JP; Mouton JW; Pahissa A; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3599-604. PubMed ID: 17646421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
    Clancy CJ; Yu VL; Morris AJ; Snydman DR; Nguyen MH
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3171-7. PubMed ID: 16048920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
    Torres HA; Kontoyiannis DP; Rolston KV
    Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of fluconazole pharmacodynamics with mortality in patients with candidemia.
    Baddley JW; Patel M; Bhavnani SM; Moser SA; Andes DR
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3022-8. PubMed ID: 18591269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.
    Lacassin F; Damond F; Chochillon C; Longuet P; Lebras J; Vilde JL; Leport C
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1961-3. PubMed ID: 8843316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EUCAST technical note on fluconazole.
    European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
    Clin Microbiol Infect; 2008 Feb; 14(2):193-5. PubMed ID: 18070130
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.
    Pai MP; Turpin RS; Garey KW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):35-9. PubMed ID: 17101684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.
    Wenisch C; Moore CB; Krause R; Presterl E; Pichna P; Denning DW
    J Clin Microbiol; 2001 Jul; 39(7):2458-62. PubMed ID: 11427554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.
    Pfaller MA; Diekema DJ; Sheehan DJ
    Clin Microbiol Rev; 2006 Apr; 19(2):435-47. PubMed ID: 16614256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
    Cuesta I; Bielza C; Cuenca-Estrella M; Larrañaga P; Rodríguez-Tudela JL
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1541-6. PubMed ID: 20124002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
    Andes D; van Ogtrop M
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.
    Eschenauer GA; Carver PL; Patel TS; Lin SW; Klinker KP; Pai MP; Lam SW
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
    Clancy CJ; Staley B; Nguyen MH
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data mining validation of fluconazole breakpoints established by the European Committee on Antimicrobial Susceptibility Testing.
    Cuesta I; Bielza C; Larrañaga P; Cuenca-Estrella M; Laguna F; Rodriguez-Pardo D; Almirante B; Pahissa A; Rodríguez-Tudela JL
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2949-54. PubMed ID: 19433568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.
    Heald AE; Cox GM; Schell WA; Bartlett JA; Perfect JR
    AIDS; 1996 Mar; 10(3):263-8. PubMed ID: 8882665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients.
    Bussaratid V; Tansupasawasdikul S; Simpson A; Pitisuttithum P; Phonrat B; Howe P; White NJ
    J Med Assoc Thai; 2002 Jul; 85(7):757-64. PubMed ID: 12296406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
    Quereda C; Polanco AM; Giner C; Sánchez-Sousa A; Pereira E; Navas E; Fortún J; Guerrero A; Baquero F
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):30-7. PubMed ID: 8641300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole for the treatment of candidiasis: 15 years experience.
    Cha R; Sobel JD
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):357-66. PubMed ID: 15482201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.